Clinical Trial

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-12 -> 2026-12 2026-06-13
minor Completion pushed: 2025-12 -> 2026-12 2026-06-13
Trial Details
NCT Number NCT06974929
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Breast Cancer
Enrollment 80 participants
Start Date 2025-05-22
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-12